Abstract
Advances in the use of lentiviral vectors for gene therapy applications have created a need for large-scale manufacture of clinical-grade viral vectors for transfer of genetic materials. Lentiviral vectors can transduce a wide range of cell types and integrate into the host genome of dividing and nondividing cells, resulting in long-term expression of the transgene both in vitro and in vivo. In this chapter, we present a method to transfect human cells, creating an easy platform to produce lentiviral vectors for CAR-T cell application.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Brentjens RJ, Davila ML, Riviere I et al (2013) CD19-targeted t cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 5:177ra38. https://doi.org/10.1126/scitranslmed.3005930
Kochenderfer JN, Dudley ME, Carpenter RO et al (2013) Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood 122:151. https://doi.org/10.1182/blood-2013-08-519413.R.E.G
Kochenderfer JN, Dudley ME, Kassim SH et al (2015) Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol 33:540–549. https://doi.org/10.1200/JCO.2014.56.2025
Kalos M, Levine BL, Porter DL et al (2011) T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 3:95ra73. https://doi.org/10.1126/scitranslmed.3002842
Beatty GL, Haas AR, Maus MV et al (2014) Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce antitumor activity in solid malignancies. Cancer Immunol Res 2:112–120. https://doi.org/10.1158/2326-6066.CIR-13-0170
Huls MH, Figliola MJ, Dawson MJ et al (2013) Clinical application of sleeping beauty and artificial antigen presenting cells to genetically modify T cells from peripheral and umbilical cord blood. J Vis Exp 72:e50070. https://doi.org/10.3791/50070
Singh H, Figliola MJ, Dawson MJ et al (2013) Manufacture of clinical-grade CD19-specific T cells stably expressing chimeric antigen receptor using sleeping beauty system and artificial antigen presenting cells. PLoS One 8:e64138. https://doi.org/10.1371/journal.pone.0064138
Morita D, Nishio N, Saito S et al (2018) Enhanced expression of anti-CD19 chimeric antigen receptor in piggyBac transposon-engineered T cells. Mol Ther Methods Clin Dev 8:131–140. https://doi.org/10.1016/j.omtm.2017.12.003
Jensen MC, Clarke P, Tan G et al (2000) Human T Lymphocyte Genetic Modification with Naked DNA. Mol Ther 1:49–55. https://doi.org/10.1006/mthe.1999.0012
Suerth JD, Schambach A, Baum C (2012) Genetic modification of lymphocytes by retrovirus-based vectors. Curr Opin Immunol 24:598–608. https://doi.org/10.1016/j.coi.2012.08.007
Merten O-W (2004) State-of-the-art of the production of retroviral vectors. J Gene Med 6:S105–S124. https://doi.org/10.1002/jgm.499
Merten O-W, Charrier S, Laroudie N et al (2011) Large-scale manufacture and characterization of a lentiviral vector produced for clinical ex vivo gene therapy application. Hum Gene Ther 22:343–356. https://doi.org/10.1089/hum.2010.060
van der Loo JCM, Wright JF (2016) Progress and challenges in viral vector manufacturing. Hum Mol Genet 25:R42–R52. https://doi.org/10.1093/hmg/ddv451
Picanço-Castro V, Fontes AM, Russo-Carbolante EMDS, Covas DT (2008) Lentiviral-mediated gene transfer – a patent review. Expert Opin Ther Pat 18:525–539. https://doi.org/10.1517/13543776.18.5.525
DuBridge RB, Tang P, Hsia HC et al (1987) Analysis of mutation in human cells by using an Epstein-Barr virus shuttle system. Mol Cell Biol 7:379–387
Gama-Norton L, Botezatu L, Herrmann S et al (2011) Lentivirus production is influenced by SV40 large T-antigen and chromosomal integration of the vector in HEK293 cells. Hum Gene Ther 22:1269–1279. https://doi.org/10.1089/hum.2010.143
Graessmann M, Menne J, Liebler M et al (1989) Helper activity for gene expression, a novel function of the SV40 enhancer. Nucleic Acids Res 17:6603–6612
Acknowledgments
The authors acknowledge the financial support of: São Paulo Research Foundation—FAPESP (2016/08374-5); the National Council for Scientific and Technological Development—CNPq (381128/2018-0); Research, Innovation, and Dissemination Centers—RIDC (2013/08135-2); and the National Institute of Science and Technology in Stem Cell and Cell Therapy—INCTC (465539/2014-9). The authors also acknowledge financial support from Secretaria Executiva do Ministério da Saúde (SE/MS), Departamento de Economia da Saúde, Investimentos e Desenvolvimento (DESID/SE), Programa Nacional de Apoio à Atenção Oncológica (PRONON) Process 25000.189625/2016-16.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Moço, P.D., de Abreu Neto, M.S., Fantacini, D.M.C., Picanço-Castro, V. (2020). Optimized Production of Lentiviral Vectors for CAR-T Cell. In: Swiech, K., Malmegrim, K., Picanço-Castro, V. (eds) Chimeric Antigen Receptor T Cells. Methods in Molecular Biology, vol 2086. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-0146-4_5
Download citation
DOI: https://doi.org/10.1007/978-1-0716-0146-4_5
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-0716-0145-7
Online ISBN: 978-1-0716-0146-4
eBook Packages: Springer Protocols